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L E T T E R T O TH E E D I T O R
Response to letter to the editor regarding “Efficacy of adding
ramipril (VAsotop) to the combination of furosemide (Lasix)
and pimobendan (VEtmedin) in dogs with mitral valve
degeneration: The VALVE trial”
Dear editor,
We appreciate the interest in our VALVE trial by Dr Atkins and others.
The authors open an important discussion and raise several interest-
ing questions that we would like to address. However, we would like
to point out that their letter to the editor appears to start with a mis-
understanding. The aim or the primary hypothesis of the VALVE trial
was not to address whether pimobendan “is all that is needed beyond
loop diuretics to manage CHF in MMVD.” The only aim of the VALVE
trial was to answer the question in dogs with MMVD that had
reached the stage of congestive heart failure (CHF), ACVIM stage C
or D, if the addition of an angiotensin converting enzyme inhibitor (ACEI)
to the basic treatment of a loop diuretic combined with pimobendan is
superior to this basic treatment. It is our opinion that this question has
been considered clinically relevant by the veterinary community for
quite some time.
Please allow us to further elaborate on the historical background
of the ACEI issue and the underlying evidence. Approximately
30 years ago, ACEI found their way into veterinary cardiology and
their use made pathophysiological sense. Subsequently, the
IMPROVE,1 LIVE,2 and BENCH3 studies led to the approval of ACE
inhibitors for dogs. These trials were groundbreaking in veterinary car-
diovascular medicine, being large controlled clinical multicenter trials.
However, it should be noted that they do not meet the CONSORT
recommendations, which is mandatory for trials of this size conducted
today.
At about the same time, the term “evidence-based medicine,”
first mentioned in 1990 in human medicine,4 also found its way into
the veterinary community, and was further defined in 2005.5 For
many years, ACEI use in veterinary medicine was based on good evi-
dence, the evidence being based on pathophysiological logic, experi-
mental animals, extrapolation from human medicine, small veterinary
studies, and expert opinion.
In fact, ACEI had been advised and used for many years to treat
preclinical heart disease in dogs. However, subsequently it was
shown that the systemic RAAS system was not measurably acti-
vated in MMVD, if furosemide was not part of the treatment.6,7
This raised the question as to whether ACEI were beneficial in
dogs with MMVD before the development of congestion and
before the use of diuretics. Nevertheless, ACEI inhibitors contin-
ued to be widely used in dogs with preclinical MMVD (ACVIM
stage B) for many years, and still are.
Then came the SVEP trial, a prospective randomized study which
failed to show any benefit of enalapril in dogs with MMVD, when
administered before the clinical occurrence of congestion.8 There was
no measurable benefit demonstrated, neither in dogs with normal
heart size (which today would be called ACVIM stage B1), nor in dogs
with demonstrable compensatory left ventricular volume overload
(which today would be classified as ACVIM stage B2). Despite this
evidence, ACEI were still recommended in dogs with MMVD in the
noncongested phase. Some arguments for ignoring the results of the
SVEP trial were inadequate dosage and the inclusion of only one
breed, the Cavalier King Charles Spaniel, which might not be repre-
sentative of other breeds with the same disease. Next came a study
similar to the SVEP trial, performed and published by Atkins et al.9
This trial had some different aspects from the SVEP trial, specifically
multiple breeds were enrolled and a reasonable dosage of ACEI was
chosen. This second prospective randomized trial did not show a sta-
tistical difference between dogs on an ACEI and those on placebo
concerning the primary endpoint.9 In this publication, the authors
carefully analyzed the data and offered plausible reasons to explain
this unexpected result. One consideration was the possibility that
starting ACEI treatment could be harmful to a certain subgroup of
dogs with MMVD, and that if these dogs were excluded from the
study, a benefit might be shown. One major problem with that argu-
ment is the fact that no known parameter could identify the proposed
subgroup of dogs, at least at the present time to our knowledge.
Despite statistical nonsuperiority of ACEI over placebo in this
second study, ACEI still are widely used in dogs with MMVD in
ACVIM stages B1 and B2. In dogs with MMVD and decompensation
(which today would be called ACVIM stage C), the usefulness of ACEI
was not questioned, and they were still broadly recommended
and used.
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Two studies subsequently were performed and published that
evaluated an ACEI and pimobendan in dogs with MMVD, with treat-
ment starting at the time of decompensation, based on objective evi-
dence of pulmonary edema on radiographs.10,11 Both studies
demonstrated the superiority of pimobendan over benazepril.
However, a primary criticism of these studies was that they both
lacked a treatment arm including both pimobendan plus an ACEI. Con-
sequently, ACEI still are recommended and broadly used, based on
expert opinion.12,13
Now, after this historical review, let us explain the background
of the VALVE trial. The VALVE trial was started very soon after
the QUEST trial had ended.11 The goal of the VALVE trial was to
answer whether adding ACEI to furosemide plus pimobendan
would improve outcome, and most VALVE coauthors had already
been involved in the QUEST trial. To be consistent and credible,
the authors largely adopted the QUEST trial's study protocol with
some differences. In both the QUEST and the VALVE trials, the
following features were identical: (a) dogs had to be in an
advanced stage of MMVD with pulmonary edema objectively pre-
sent on thoracic radiographs; (b) the study was not placebo-con-
trolled, but the study authors were blinded to the treatment as the
drugs were provided to the clients using a provider; (c) treatment
failure was defined as decompensation despite the use of very
high doses of furosemide. This dosage had been set at 12 mg/kg/d
in the QUEST trial and at 15 mg/kg/d in the VALVE trial. Admit-
tedly, these are very high dosages. Nevertheless, this was the defi-
nition of treatment failure in these respective studies. Please note,
however, that the median maximal dose of furosemide in the
VALVE trial was 9.1 mg/kg/d; we will further elaborate on the
furosemide dose below.
In their letter to the editor, Atkins and colleagues point out the
lack of additional treatments and comment that in the VALVE study
we primarily increased the diuretic dose instead of adding various
other drugs. However, we simply followed our protocol, which was
similar to that of the QUEST trial. Changing and modifying the treat-
ment options by adding different drugs might have led to unwanted
effects of those drugs, either positive or negative, and ultimately
might have influenced the answer to the primary question: “Does the
addition of an ACEI improve the outcome of our patient population?”
Of course, a study always generates new questions, some of
which were raised by Dr Atkins and colleagues in their letter to the
editor. Was there an aldosterone breakthrough? Was the dose of the
ACEI not high enough? Would the use of a mineralocorticoid receptor
antagonist (MRA) be more beneficial?
Atkins et al. cite two studies that suggest an effect of spi-
ronolactone, but both studies were not performed with the currently
recommended standard treatment using pimobendan. The only evi-
dence, based on a published study, concerns the use of spi-
ronolactone.14 One of the cited studies had only a few dogs receiving
pimobendan14 and this study's conclusions have been questioned.15
The second study, the Benazepril Spironolactone Study (BESST), is
not yet published, but apparently these dogs also had not received
pimobendan. Therefore, these studies also do not answer the
question of whether or not dogs that receive pimobendan and a
diuretic will benefit from the use of an ACEI as well as an MRA.
Concerning the use of spironolactone in the VALVE trial, it is
important to realize that the 13 dogs on spironolactone only referred
to dogs prescribed spironolactone at the beginning of the study. In
the course of the trial, 61 dogs eventually received spironolactone
during progression of their disease (32 dogs in the dual therapy
[DT] group and 29 dogs in the triple therapy [TT] group). However,
we fully agree with Atkins and others that additional large-scale stud-
ies on this subject are necessary.
Concerning the starting dosage of furosemide in our VALVE
trial, we agree that this dosage was quite high. However, it is com-
mon practice in some of our clinics to titrate the furosemide dosage
down to the minimal effective dose as opposed to titrating the dos-
age up. The patients are discharged after stabilization in the clinic on
similar diuretic dosages to prevent an immediate relapse of conges-
tion, which might lead to owner disappointment and a potential
decision for euthanasia. Once the dog has been stable for 3 days
and the owners have learned to count the resting respiration rate
(RRR), we start lowering the diuretic dose. The owners' RRR counts
can be reviewed either by telephone or clinic visits to determine the
minimal effective diuretic dose. In response to the concern raised by
Atkins and colleagues, we have analyzed the furosemide dosages at
the first and second recheck examinations. The mean furosemide
dosage for both groups at day 7 was 5.91 mg/kg/d; DT, 5.89 mg/
kg/d; TT, 5.91 mg/kg/d. After 1 month, the mean furosemide dos-
age was 5.32 mg/kg/d (DT, 4.78 mg/kg/d; TT, 5.80 mg/kg/d). These
diuretic dosages were similar to those used in the QUEST study. The
mean maximal furosemide dosage over the entire study period was
9.1 mg/kg/d.
Atkins and colleagues' next concern is the fact that RAAS sup-
pression was not assessed using biomarkers, and that the ACEI dosage
may have been inadequately low and was only doubled in 3 dogs.
Actually, as reported in our paper, the mean dosage of ACEI was
already 1.7 times higher than the dosage recommended by the manu-
facturer. Therefore, underdosing of the ACEI is an unlikely explanation
of our results.
Atkins and colleagues mention “the known favorable effects of
RAAS suppression on cardiac remodeling” supported by 2 citations.
We respectfully disagree with this statement. First, as already dis-
cussed in this response, the study by Atkins et al as well as the SVEP
trial, which both investigated a possible beneficial effect of ACEI in
MMVD to postpone the occurrence of pulmonary edema, failed to
prove this beneficial effect.8,9 Second, Atkins and colleagues cite a
recent study that again was undertaken with the primary goal to show
a beneficial effect of RAAS suppression to postpone the onset of pul-
monary edema in dogs with MMVD.16 However, this study again
failed to show this beneficial effect, and indeed there was not even a
tendency toward a beneficial effect concerning the primary study
goal. This last study did describe effects of RAAS suppression on N-
terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac size,
but it did not just use an ACEI but the combination of an ACEI with an
aldosterone antagonist.16
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A further concern of Atkins and colleagues is the pretreatment
with ACEI for several months before entering the VALVE trial.
Returning to the important study by Atkins et al9: several dogs in the
ACEI group died early in the study and it was argued that if these dogs
had been excluded from the statistical analysis, ACEI would have been
proven to have a positive effect on the course of the disease. If we
adopt the same line of reasoning for our VALVE trial, we could con-
clude that these particular dogs, supposedly responding negatively to
ACEI, never actually entered the VALVE trial because they would
have been dead before they could have started the VALVE trial. Addi-
tionally, we tested preinclusion ACEI use in the multivariate analysis
and found no effect. Furthermore, withdrawing the ACEI in the DT
group might have disadvantaged dogs only in the DT group and not
the TT group. We also tested the possible effect of center, because
the number of dogs enrolled at the University of Munich (where the
study was initiated) was significantly higher, compared with the other
3 centers. However, there was no significant difference in outcome
among the study centers.
Finally, Atkins and others raised the question of owner compli-
ance, which we can answer to be the same in both groups. Very
importantly, no dog was lost because of renal compromise, or
excluded from the study because of polyuria, polydipsia, or renal
dysfunction.
We fully agree with Atkins and colleagues that our VALVE trial
does not provide the final answer concerning RAAS suppression in
dogs with MMVD and CHF. However, the VALVE trial is a large, pro-
spective, randomized, multicenter study with a very high event rate
that did not show any survival benefit with respect to the use of an
ACEI in dogs with advanced MMVD. Therefore, given the data avail-
able today, we cannot in good faith recommend adding an ACEI to
the basic treatment consisting of furosemide and pimobendan in dogs
with MMVD in ACVIM stage C.
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